NANOBIOTIX (EPA:NANO) | Finanzwire

Basculer en Français

11005	Companies
241112	Keywords
169694	Articles
129797	Press releases

Home
Companies
NANOBIOTIX

PRESS RELEASE

published on 05/28/2024 at 22:15, 2 years 3 months ago

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
Nanobiotix to present new data from Phase 1 immunotherapy program at 2024 ASCO meeting followed by investor conference call. Details for the call provided

Investor Conference Call Immunotherapy ASCO 2024 NANOBIOTIX Phase 1
BRIEF

published on 05/23/2024 at 22:20, 2 years 3 months ago

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

Biotechnology Cancer Treatment Webcast NANOBIOTIX Jefferies Global Healthcare Conference
PRESS RELEASE

published on 05/23/2024 at 22:15, 2 years 3 months ago

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
Nanobiotix to present at the Jefferies Global Healthcare Conference on June 5, 2024, with Bart Van Rhijn, CFO, participating in a fireside chat. Company pioneering physics-based approaches for cancer treatment

Cancer Treatment Biotechnology Company NANOBIOTIX Jefferies Global Healthcare Conference Physics-based Approaches
BRIEF

published on 05/21/2024 at 22:20, 2 years 3 months ago

Nanobiotix Announces Advancement in NBTXR3 Development and Strategic Collaboration

Biotechnology Cancer Therapy NANOBIOTIX NBTXR3 Janssen Collaboration
PRESS RELEASE

published on 05/21/2024 at 22:15, 2 years 3 months ago

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
Nanobiotix announces progress in global NBTXR3 development collaboration, highlighting robust pipeline and pathway to long-term growth in cancer treatment. Updates include US FDA approvals and strategic study modifications

Cancer Treatment NANOBIOTIX NBTXR3 Global Development FDA Approvals
BRIEF

published on 05/14/2024 at 22:20, 2 years 4 months ago

NANOBIOTIX Launches Phase 2 Lung Cancer Treatment Study with FDA Approval

FDA Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer
PRESS RELEASE

published on 05/14/2024 at 22:15, 2 years 4 months ago

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
Nanobiotix announces US FDA protocol acceptance for new randomized Phase 2 study on NBTXR3 for stage three lung cancer patients

Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer FDA Protocol

Accesswire

Published on 09/16/2026 at 21:30, 1 hour 41 minutes ago

Torq Completes $1.7 Million Private Placement
Published on 09/16/2026 at 16:55, 6 hours 16 minutes ago

CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 8 hours 11 minutes ago

2026 Canada's Top 40 Under 40(R) Honourees Announced
Published on 09/16/2026 at 14:00, 9 hours 11 minutes ago

Ameriwest Awaits Bornite Core Assay Results and Provides Q3 2026 Corporate Update
Published on 09/16/2026 at 13:30, 9 hours 41 minutes ago

Sterling Extends Core MEPS Copper Zone to 700m; Intersects 200m of 0.53% CuEq Including 102m of 0.81% CuEq

View all ACCESSWIRE

EQS Group

Published on 09/16/2026 at 22:33, 37 minutes ago

EQS-Adhoc: Bilfinger adjusts outlook for 2026 and resolves program “Agile”
Published on 09/16/2026 at 21:15, 1 hour 55 minutes ago

Gastech 2026 in Bangkok Converts Global Energy Ambition into Billions of Dollars in Deals
Published on 09/16/2026 at 20:27, 2 hours 43 minutes ago

EQS-Adhoc: REPLOID Group AG resolves to issue convertible notes in an aggregate principal amount of up to EUR 30 million
Published on 09/16/2026 at 19:05, 4 hours 5 minutes ago

EcoFlow to showcase its open home energy ecosystem at Solar & Storage Live Zurich 2026
Published on 09/16/2026 at 18:22, 4 hours 49 minutes ago

EQS-Adhoc: elumeo SE resolves on a capital increase against cash contributions, ex-cluding pre-emptive rights, and a move to the Scale segment

Les Echos

Published on 09/16/2026 at 20:46, 2 hours 24 minutes ago

LNA SANTE : 2026 First Half Results
Published on 09/16/2026 at 17:45, 5 hours 26 minutes ago

5th edition of “On the way up” show
Published on 09/16/2026 at 17:45, 5 hours 26 minutes ago

Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 16 hours 11 minutes ago

bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 5 hours ago

Report on the Combined General Meeting of the 10th of September 2026

View all LES ECHOS COMFI WIRE